Sunday, 1 Jun 2025
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms & Conditions
  • DMCA
Subscribe
Brinks Report
  • Featured
  • Money Matters
  • Business
  • IPL
  • Technology
  • Automobile
  • Entertainment
  • Sports
  • More
    • People
    • World
    • Health and Wellness
    • Horoscope
  • Today’s News
  • 🔥
  • World
  • Business
  • Economy
  • Technology
  • Automobile
  • IPL
  • People
  • Sports
  • IPL 2025
  • Entertainment
Font ResizerAa
Brinks ReportBrinks Report
Search
  • Featured
  • Money Matters
  • Business
  • IPL
  • Technology
  • Automobile
  • Entertainment
  • Sports
  • More
    • People
    • World
    • Health and Wellness
    • Horoscope
  • Today’s News
Have an existing account? Sign In
Follow US
© 2024-2025 Brinks Report. All content, including text, images, and other media, is copyrighted.
Brinks Report > Blog > Health and Wellness > Why Everyone’s Talking About Natco Pharma’s Risdiplam Decision!
Health and Wellness

Why Everyone’s Talking About Natco Pharma’s Risdiplam Decision!

Ankita Das
Last updated: April 8, 2025 12:30 pm
Ankita Das
Share
Natco pharma updates on risdiplam launch in india
SHARE
Trulli

Natco Pharma has shared an update regarding the launch of the generic version of Risdiplam in India.

The company has received many questions from investors and patients about when the drug will be available, its price, and other details. To clarify, Natco said that the Delhi High Court had earlier rejected Roche’s request to stop Natco from launching the drug. However, Roche has now appealed this decision, and the higher court has asked both parties to maintain the current situation until a final decision is made.

Trulli

Read More: Sun Pharma Rolls Out Revolutionary Acid Blocker FEXUCLUE in India

Because the case is still going on, Natco does not want to comment further. But the company made it clear that it will only launch the drug after getting a clear go-ahead from the higher court, which is expected soon.

Also See: Morepen Labs Cracks the Chinese Market with NMPA Approval for Loratadine! What This Means for Global Pharma

Natco has decided to price the drug at an MRP of ₹15,900, which is in line with what it has told the court. The company also plans to support some patients with discounts through its patient access program.

Image Slider
Image 1 Image 2 Image 3
TAGGED:GenericMedicineHealthcareIndiaNatcoPharmaPharmaNewsRisdiplam
Share This Article
Facebook Whatsapp Whatsapp Copy Link Print
What do you think?
Love0
Sad0
Happy0
Joy0
Sleepy0
Angry0
Surprise0
Previous Article Trade wars + recession = oil crash? Goldman warns market shift Trade Wars + Recession = Oil Crash? Goldman Warns Market Shift
Next Article Godrej properties shatters sales record with ₹10,163 cr in q4 fy25 Godrej Properties Shatters Sales Record with ₹10,163 Cr in Q4 FY25
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Your Trusted Source for Accurate and Timely Updates!

Brink’s Report delivers fresh, unbiased, and engaging content across politics, business, tech, entertainment, and more. From breaking news to deep dives, we keep you informed—and intrigued—with accurate reporting and diverse perspectives. Explore the world, one story at a time.
FacebookLike
XFollow
RSS FeedFollow
Ad image

You Might Also Like

Best magnesium supplements for health: benefits & timing
Health and Wellness

Do You Know What’s the Best Time to Take Magnesium for Maximum Benefits? See Which Supplement Works Wonders!

By
Ankita Das
Biocon’s q4 profit soars 154% yoy to ₹344 crore in fy25
BusinessHealth and Wellness

Biocon’s Q4 Results: Profit Jumps 154% YoY to ₹344 Crore on Strong Performance

By
Ankita Das
Male fertility awareness
Health and Wellness

Science Meets Spectacle: Sperm Race in LA Fuels Male Fertility Awareness Movement

By
Dolon Mondal
Health emergency in pune: contaminated water suspected in gbs outbreak
Health and Wellness

Health Emergency in Pune: Contaminated Water Suspected in GBS Outbreak

By
Dolon Mondal
Ad image

About US


Brink’s Report delivers fresh, unbiased, and engaging content across politics, business, tech, entertainment, and more. From breaking news to deep dives, we keep you informed—and intrigued—with accurate reporting and diverse perspectives. Explore the world, one story at a time.

Top Categories
  • World
  • Business
  • Economy
  • Technology
Usefull Links
  • Contact Us
  • About Us
  • Privacy Policy
  • DMCA

© 2024-2025 Brinks Report. All content, including text, images, and other media, is copyrighted.